Cargando…
TP53 mutation variant allele frequency of ≥10% is associated with poor prognosis in therapy-related myeloid neoplasms
Revised diagnostic criteria for myeloid neoplasms (MN) issued by the International Consensus Classification (ICC) and the World Health Organization (WHO) recommended major change pertaining to TP53-mutated (TP53(mut)) MN. However, these assertions have not been specifically examined in therapy-relat...
Autores principales: | Shah, Mithun Vinod, Tran, Elizabeth Ngoc Hoa, Shah, Syed, Chhetri, Rakchha, Baranwal, Anmol, Ladon, Dariusz, Shultz, Carl, Al-Kali, Aref, Brown, Anna L., Chen, Dong, Scott, Hamish S., Greipp, Patricia, Thomas, Daniel, Alkhateeb, Hassan B., Singhal, Deepak, Gangat, Naseema, Kumar, Sharad, Patnaik, Mrinal M., Hahn, Christopher N., Kok, Chung Hoow, Tefferi, Ayalew, Hiwase, Devendra K. |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Nature Publishing Group UK
2023
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10090194/ https://www.ncbi.nlm.nih.gov/pubmed/37041128 http://dx.doi.org/10.1038/s41408-023-00821-x |
Ejemplares similares
-
Outcomes following venetoclax‐based treatment in therapy‐related myeloid neoplasms
por: Shah, Mithun Vinod, et al.
Publicado: (2022) -
P580: CHARACTERISTICS AND OUTCOMES OF PATIENTS WITH WT1 MUTATED MYELOID NEOPLASMS: MAYO CLINIC EXPERIENCE
por: Basmaci, Rami, et al.
Publicado: (2023) -
Treatment outcome of clonal cytopenias of undetermined significance: a single-institution retrospective study
por: Xie, Zhuoer, et al.
Publicado: (2021) -
Molecular predictors of response to venetoclax plus hypomethylating agent in treatment-naïve acute myeloid leukemia
por: Gangat, Naseema, et al.
Publicado: (2022) -
P1346: THE IMPACT OF CYTOTOXIC THERAPY ON THE RISK OF PROGRESSION AND DEATH IN PATIENTS WITH CLONAL CYTOPENIA OF UNDETERMINED SIGNIFICANCE.
por: Marissa, LI, et al.
Publicado: (2023)